Ponezumab
Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.[1][2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | beta-amyloid |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6552H10158N1730O2090S52 |
| Molar mass | 148272.48 g·mol−1 |
  (what is this?) (verify) | |
Ponezumab was developed by Pfizer Inc. In November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial.[3]
References
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab" (PDF). American Medical Association.
- Popescu CD, Trofin D, Ignat B, Matei D (2014). "New Aspects of Therapeutic Management in Alzheimer`s Disease". In Atta-ur-Rahman (ed.). Frontiers in Clinical Drug Research: Alzheimer Disorders. Vol. 3. Sharjah: Bentham Science Publishers. p. 55. doi:10.2174/9781681080680115030004. ISBN 978-1-68108-068-0.
- "Alzforum".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.